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The use of pesticides such as aluminium phosphide (AlP) has increased in the recent years and improved the quantity 
and quality of agricultural products in a number of developing countries. The downside is that AlP causes severe chronic 
and acute health effects that have reached major proportions in countries such as India, Iran, Bangladesh, and Jordan. 
Nearly 300,000 people die due to pesticide poisoning in the world every year. Poisoning with AlP accounts for many of 
these deaths. Unfortunately, at the same time, there is no standard treatment for it. The aim of this article is to give a brief 
review of AlP poisoning and propose a treatment flowchart based on the knowledge gained so far. For this purpose we 
reviewed all articles on the management of AlP poisoning published from 2000 till now. Using a modified Delphi design, 
we have designed a handy flowchart that could be used as a guide for AlP poisoning management of patients in emergency 
centres.
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Pesticide use has increased the quantity and quality of 
agricultural products in a number of developing countries. 
Although its wise use may improve the quality of life and 
livelihood of their residents, improper use may cause severe 
chronic and acute poisoning. In fact, nearly 300,000 people 
in the world die every year due to pesticide poisoning (1).
Metal phosphides make a large proportion of the 
pesticides/fumigants that are currently being used. The use 
of aluminium, magnesium, and calcium phosphides has 
become popular in developing countries mainly because 
they are potent, cheap, and have no undesirable effects on 
agricultural products. Yet, the risk of mortality associated 
with phosphide poisoning in humans ranges between 30 % 
and 100 % (2).
Aluminium phosphide (AlP) is used for crop protection 
in storage and transport such as silos, ships, and trains (3). 
It is quite common in Iran (especially northern Iran) in the 
form of tablets (hence the common term “rice tablets”) due 
to low cost, high potency, and ready availability, but so is 
the risk of poisoning and death. Northern Iranian provinces 
report a rather high AlP poisoning rate (3), for which reason 
Iran has been trying to control AlP production and purchase, 
but the tablets are still being smuggled into the country and 
available to the lay people at low prices.
Current figures say that AlP is one of the most common 
causes of poisoning deaths in India, Sri Lanka, Iran, Oman, 
and Morocco (4-8) but not in European and North American 
countries (9, 10). Reports of mortality due to AlP poisoning 
vary across the world. Between 1997 and 2003, UK reported 
only 93 cases of AlP poisoning, all of them accidental, and 
only one resulted in a death (4). In Germany, between 1983 
and 2003, only 188 cases of AlP poisoning were reported, 
65 % of which accidental and mainly inhalational. They 
had mainly caused transient irritation of the gastrointestinal 
and respiratory system and none resulted in a death. The 
remaining, intentional poisonings caused two deaths (11). 
By contrast, AlP poisoning caused 146 deaths in Iran 
between 2000 and 2007 (8,12). According to Hosseinian et 
al. (13), more than 90 % of these poisonings are suicidal. 
In Tehran it seems to be the most common suicide agent 
(14), especially in people below 30 years of age. The 
mortality rate ranges between 18.6 % and 24 % and is higher 
in the rural areas (15).
In contact with water, an AlP tablet releases deadly 
phosphine gas (PH3), which has drawn interest for its use 
as a chemical weapon (4). While the danger of AlP 
poisoning is obvious, this can not be said for its treatment. 
AlP has no specific antidote, and only through shared 
experience can we increase the odds of survival by 
improving the management of AlP poisoning. (8). This 
article is one such attempt to gather recent knowledge in 
one place and suggest a management flowchart that perhaps 
best suits the circumstances in Iran and countries with 
similar issues and healthcare.
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Literature search and data pooling
We searched PubMed, Google Scholar, and Scopus for 
all articles on AlP poisoning management published from 
2000 to date. The key words we used were “aluminium 
phosphide”, “poisoning”, “toxicity”, “treatment”, and 
“management”. We reviewed the abstracts of recovered 
articles, looking specifically for those suggesting treatment 
for AlP poisoning. Duplicate articles, articles that did not 
meet the above criteria, and articles that did not add new 
data were excluded. The final pool of articles after exclusion 
consisted of seven reviews, 44 original articles, 33 case 
reports, three letters, one textbook, and five web references.
All selected articles were reviewed by the first author 
for original human data about the toxic effects of AlP and 
its management and the pooled data were discussed by all 
authors at six sessions. The final AlP poisoning management 
flowchart was designed by the corresponding author and 
reviewed and endorsed by six authors.
POOLED FINDINGS
Chemistry
Aluminium phosphide (AlP) comes as a dark grey or 
yellow crystal and AlP tablets are available under a variety 
of trade names, such as Phosfume, Synfum, Celphos, 
Phostoxin, Quickphos, Phostek, Chemfume, Degesch, 
Talunex, Alphosm, and Delicia (16). A three-gram tablet 
can release almost one gram of phosphine gas in contact 
with water. In Iran, the AlP tablet is marketed under the 
trade name of Phostoxin and contains aluminium phosphide, 
urea, and ammonium carbamate. Phosphine gas is 
flammable (16-20). To prevent spontaneous combustion the 
tablet should also contain ammonium carbamate at the 56:44 
ratio of AlP and ammonium carbamate, respectively (18).
In contact with water, AlP tablet produces phosphine, 
ammonia, and CO2. Contact with acids may even increase 
the release of PH3 (21). Phosphine gas (PH3) has a molecular 
weight of 34 Da. It is colourless, flammable, has the odour 
of spoiled fish (density: 1.52 g L-1), and is detectable at 
concentrations of 2 mg L-1 (2 ppm) or more. The spoiled 
fish odour comes from the impurities such as diphosphine 
(P2H4), methane, arsine, and extracted hydrogen and 
phosphines (3, 22).
Toxicokinetics
Absorption: After ingestion, phosphine will be released 
due to contact between AlP and water/acid in the 
gastrointestinal (GI) tract. Some phosphide may be absorbed 
by the GI tract without hydrolysis and convert into 
phosphine. Phosphine gas can rapidly be absorbed by the 
lungs and GI tract. Absorption through skin and eyes is not 
common but may happen (23).
Distribution: After ingestion, phosphine concentration 
increases in the blood and liver. This small molecule can 
easily be distributed in all tissues (24, 25).
Metabolism and elimination: Metal phosphides change 
to phosphine due to hydrolysis. The most important urine 
metabolite of phosphine is hypophosphite, but urine can 
also contain phosphate and phosphite. Phosphine itself is 
eliminated by exhalation (26). Aluminium phosphide may 
be eliminated in the urine unchanged.
Toxicodynamics
Most of the toxic effects of metal phosphides are owed 
to PH3, which is a protoplasmic poison that interferes with 
the function of the cellular enzymes and proteins. According 
to some authors (27, 28), the mechanism of its toxicity is 
electron transfer blockage and non-competitive blockage 
of cytochrome C oxidase, which inhibits oxidative 
phosphorylation and, in turn, cellular respiration and 
activation of peroxide radicals. Phosphine can inhibit 
catalase and deplete glutathione, which may result in 
cellular wall and canal dysfunction as well (29, 30).
According to Proudfoot (31), studies have shown that 
phosphine impairs cellular respiration. It inhibits the 
entrance of amino acids into the cycle of myocardial protein 
synthesis and also inhibits cytochrome C oxidase in cardiac 
cells. According to Anand et al. (32), these changes in the 
mitochondria and myocardial proteins impair cellular 
permeability to sodium, potassium, magnesium, calcium, 
and other ions and change cardiac cell wall potential. 
Phosphine-induced pathophysiological changes are more 
prominent in the myocardium, pulmonary cells, and tiny 
peripheral vessels (26).
Both AlP and phosphine inhibit cholinesterase, but this 
inhibition is unlikely to be clinically relevant (33). Another 
toxic action of phosphine is that it changes the capacity of 
haeme. In vitro studies show that humans and rats can 
absorb unhydrolysed aluminium phosphide salt, which 
keeps reacting with free haemoglobin and haemoglobin in 
normal red blood cells (RBCs) to produce haemichrome, a 
derivative of methaemoglobin (31, 34).
Levels of carbon monoxide, which can be established 
by CO-oximetry, can help diagnosis and prognosis of AlP 
poisoning. Namely, phosphine may affect oxyhaemoglobin 
that interacts with CO and cause dyshaemoglobinemia, 
which can yield high CO findings (35). 
Considering that phosphine produces free oxygen 
radicals in body tissues, it has been shown that organs with 
a higher need for oxygen (heart, lung, kidney, and liver) are 
more sensitive to the damage induced by phosphine gas, 
which is compatible with the post-mortem histopathological 
changes in these organs. In addition, Heinz bodies, which 
are indicative of the destruction of haemoglobin in vitro, 
increase to 1.25 µg mL-1 in poisoned patients (36). 
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delays and arrhythmias from hours six to twelve (45). The 
most common arrhythmias are supra-ventricular tachycardia 
(46 %), ventricular tachycardia (40 %), ventricular 
fibrillation (23 %), and atrial flutter and fibrillation (20 %) 
(46). Post-mortem findings show cardiac failure, severe and 
persistent hypotension, heart congestion, subendocardial 
infarction, pericarditis, cardiac fibre detachment due to 
oedema, fibre destruction, nonspecific vacuolation of the 
myocytes, local necrosis, neutrophil infiltration, and 
eosinophilia (40, 41, 47-50).
Electrolyte abnormalities include high or low sodium, 
potassium, and magnesium. Hypocalcaemia may also be 
detected. Hypokalaemia may precede or follow vomiting. 
Hyperkalaemia, hypernatremia, and hyponatremia are 
associated with poorer prognosis  (49). Hyper- or 
hypoglycaemia may also occur (40, 48, 50). Changes in the 
serum level of magnesium, calcium, phosphate, citrate, and 
cortisol may increase serum glucose levels, which is 
associated with poorer prognosis (25). 
Other uncommon manifestations include hepatitis, 
pancreatitis, ascites, myocardial infarction, acute 
pericarditis, pleural effusion, acute tubular necrosis (ATN), 
adrenocortical congestion with bleeding or necrosis, diffuse 
intravascular coagulation (DIC), rhabdomyolysis, and 
methaemoglobinaemia (3, 31, 42). Oesophageal stricture 
and oesophagotracheal fistula are two delayed complications 
(51-55). Most deaths occur within the first 12-24 h due to 
cardiac arrest (47). Deaths occurring after 24 h are often 
related to hepatic failure (32).
Acute poisoning due to inhalation
After inhaling small amounts of phosphine gas, patients 
generally experience respiratory tract irritation and 
dyspnoea (3). Other manifestations include dizziness, chest 
tightness, headache, nausea and vomiting, diarrhoea, ataxia, 
numbness, paraesthesia, tremor, muscular weakness, and 
diplopia (6, 38). Inhalation of high amounts of the gas can 
lead to cardiac failure, acute respiratory distress syndrome 
(ARDS), dysrhythmia, seizure, coma, and delayed 
manifestations such as liver and kidney toxicity (6, 38).
Chronic poisoning
Patients with chronic phosphine exposure, usually those 
who work in silos, have manifestations such as cough, 
dyspnoea, chest pain, drowsiness, loss of appetite, and 
epigastric pain (56). Chronic exposure to low levels of 
phosphine may induce toothache and mandibular swelling 
and necrosis (phossy jaw). Chronic dermal exposure to 
0.4 mg L-1 (0.4 ppm) of phosphine gas may cause dermal 
congestion and sensitivity (56, 57).
Laboratory findings
Diagnostic laboratory tests that can predict the outcome 
are mandatory for the management of AlP poisoning. 
Generally these include ECG, cardiac monitoring, chest 
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Toxic levels
The lethal dose of AlP in a normal 70-kg adult has been 
reported to be 500 mg (37). In the work place, air phosphine 
level of 50 mg L-1 (50 ppm) may be dangerous for health, 
and 400-600 mg L-1 (400-600 ppm) may cause death in 30 
minutes (38).
CLINICAL MANIFESTATIONS
Acute poisoning due to ingestion
The first signs and symptoms of poisoning manifest 
themselves in 10-15 min, progress very fast (32), and affect 
the cardiovascular and respiratory systems. If the tablet is 
ingested, GI irritation can also be detected. Early signs 
include nausea and vomiting, epigastric and retrosternal 
pain, dyspnoea, anxiety, irritability, and garlic or spoiled 
fish odour from the patients' breath can be detected at the 
early stages of toxicity. This odour can also be detected 
after inhalation (16). 
Early gastrointestinal signs and symptoms include 
haematemesis, vomiting, and epigastric pain. Dysphagia is 
a common but delayed complication. Endoscopy usually 
shows destructive lesions of the oesophagus and stomach, 
stomach lesions, duodenal erosions, and oesophageal 
obstruction or fistula (21).
Poisoning manifestations of the central nervous system 
generally include irritability, anxiety, dizziness, ataxia, 
numbness, paraesthesia, and tremor. However, these signs 
and symptoms are not prominent, unless important 
complications such as hypoxia or hypotension occur. 
Delayed and severe neurological signs include delirium, 
seizure, and coma (39). Persistent shock can cause 
drowsiness, delirium, and coma.
The most common hepatotoxicity findings in patients 
who ingested AlP tablets are elevated aspartate transaminase 
and alanine transaminase (40-43). Jaundice, if manifested, 
may be a sign of liver impairment (40). In deceased patients 
the most common histopathological findings are cytoplasmic 
vacuolation of the hepatocytes and sinusoidal congestion 
(44).
The most common respiratory signs and symptoms are 
tachypnoea, dyspnoea, crepitation, and rhonchi. Respiratory 
distress syndrome and pulmonary oedema are common in 
adult patients and accompany the accumulation of bloody 
or full-protein liquids in the pleural space (32).
Cardiac signs and symptoms include increased size of 
the ventricles, left ventricular and septal hypokinesia, 
akinesia, decreased cardiac output, severe hypotension, 
increased systemic venous pressure, normal capillary wedge 
pressure, and inappropriate systemic vasoconstriction (21). 
Electrocardiographic (ECG) changes depend on the time 
elapsed since AlP ingestion. Sinus tachycardia is prominent 
within the first three to six hours, followed by conductive 
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X-ray, blood sugar, arterial or venous blood gas analysis 
(ABG or VBG), serum electrolytes, complete blood count 
(CBC), and liver and kidney function tests. Hypo- and 
hypermagnesemia are associated with cardiotoxicity and 
vast myocyte destruction (3). Poisoned patient may have 
high, low, or even normal levels of magnesium (40, 49, 58). 
CBC can show low white and red blood cell counts. 
Intravascular haemolysis, methaemoglobinaemia, or 
microangiopathic haemolysis are less common 
complications of AlP poisoning (34, 58- 60). Serum sodium 
and potassium may either be high or low. Hypokalaemia is 
generally detected after tablet ingestion and is probably 
caused by vomiting or catecholamine release (31). 
Hypoglycaemia can be due to gluconeogenesis, 
glycogenolysis, or adrenal insufficiency. Hypoglycaemia 
is common and can be severe and persistent (57). It is also 
associated with a poorer outcome (25, 60, 61). ABG analysis 
can detect metabolic acidosis or mixed metabolic acidosis 
and respiratory alkalosis (31).
Chest x-ray generally shows pulmonary oedema, pleural 
effusion, and sub-pericardial bleedings.
ECG changes include sinus tachycardia, ST changes, 
inverted T, myocardial infarction, AV block (especially the 
right bundle branch block), and complete heart block (31, 
62) in addition to the previously mentioned complications. 
If the patient survives the first 24 hours, ECG changes will 
normalize in 10-25 days. Life-threatening changes can be 
detected by the ECG in as many as 50 % of the patients. 
(41).
Biosample testing for PH3
Phosphine is rapidly oxidised to phosphate and 
hypophosphite and is not tested for in clinical assessments 
(19). Identifying its presence in tissue is not necessary for 
the diagnosis of AlP poisoning.
However, qualitative analysis of PH3 is important for 
forensic purposes. Forensic evaluation includes the analysis 
of expiratory air (50 % of the AlP-poisoned patients have 
positive expiratory tests) (3), stomach content (vomits and/
or gastric lavage), which can be collected in clean glass 
samplers, urine (only for PH3 metabolites due to rapid 
oxidation of the gas), and liver. Heated in acidic environment, 
liver tissue releases PH3 in the tissue matrix, which makes 
it a valuable sample for post mortem identification of 
phosphine. Blood, however, is not suitable due to the 
oxidative metabolism of phosphines (36).
Routine methods of AlP detection and quantification
Phosphine is routinely detected in biosamples by 
chemical qualitative colour tests such as silver nitrate (0.1 N 
or 16.987 g L-1), mercury chloride in ethanol, acidic 
potassium permanganate (0.1 N or 79.017 g L-1), or 0.5 % 
mercury diethylthiocarbamate. The sample is heated in 
acidic environment to release PH3, which interacts with the 
chemical and generates a specific colour.
Detection of PH3 with silver nitrate paper is perhaps the 
most common and valuable in clinical and forensic tests 
and can be used on biosamples such as expiratory air and 
stomach content. Silver nitrate reacts with PH3 and changes 
the colour of the paper to dark grey or black (63). The 
method is sensitive enough to detect PH3 at concentrations 
as low as 0.05 mg L-1 (0.05 ppm).
Less common tests use ammonium, arsine, and 
ammonium molybdate as detectors. The first two are used 
on expiratory air samples (26) but are seldom used for 
clinical testing over validity issues. The ammonium 
molybdate test is used on stomach content.
Potentiometry, in turn, is a semi-quantitative test used 
to determine the concentration of PH3. PH3 reacts with 
mercury chloride [PH3 + 3HgCl2 -> P (HgCl)3 + 3HCl] to 
produce a series of changes in the oxidation-reduction 
potential and consequently in the electrical conduction of 
electrochemical cells. The concentration of PH3 can also 
be calculated from HCl released from sodium hydroxide 
(64). Currently the most sensitive and specific quantification 
method is chromatography with a nitrogen-phosphorus 
detector, as it can measure even the lowest levels of PH3 in 
the air (65).
Differential diagnosis
The signs and symptoms of mild poisoning are similar 
to the signs and symptoms of upper respiratory infections. 
In severe cases of poisoning, contact with PH3 can be 
misdiagnosed with cardio-pulmonary oedema, viral, and 
bacterial pneumonia, or ARDS due to other causes (32). 
Signs and symptoms of poisoning with zinc phosphide can 
be similar to AlP poisoning, but are usually slower to 
manifest themselves, and zinc phosphide poisoning has a 
lower mortality rate (66, 67).
Treatment of acute poisoning
The proposed AlP poisoning treatment flowchart (Figure 
1) is mostly intended for Iran and can be used as a unified 
method throughout the country.
After the presentation of a patient with suspected history 
of AlP poisoning, the first step is to diagnose if the patient 
has really been exposed to AlP using the above-mentioned 
diagnostic tests. Whoever of the medical staff is checking 
the patient should wear a full-face mask and rubber gloves. 
Bear in mind that masks with tiny pores cannot prevent PH3 
exposure (65). If the patient's clothes are contaminated, 
they should be taken off. Contaminated skin and eyes should 
be thoroughly washed (3). The vomit can contain PH3 and 
can be dangerous to others, so it should be cleaned and 
disposed of. Whoever does the cleaning should be warned 
about the dangers. In inhalational exposures the patient 
should immediately be removed from the contaminated 
environment, his/her clothes changed, and his/her skin 
washed, taking recommended precautions.
Hashemi-Domeneh, et al. A review of aluminium phosphide poisoning and a flowchart to treat it
Arh Hig Rada Toksikol 2016;67:183-193
187Hashemi-Domeneh, et al. A review of aluminium phosphide poisoning and a flowchart to treat itArh Hig Rada Toksikol 2016;67:183-193
188 Hashemi-Domeneh, et al. A review of aluminium phosphide poisoning and a flowchart to treat itArh Hig Rada Toksikol 2016;67:183-193
As there is no specific antidote for AlP poisoning, the 
cornerstone of therapy is supportive care. Timing 
significantly affects the prognosis. If AlP poisoning is 
suspected based on the history and physical examination, 
treatment must not be delayed until test results are confirmed 
(24). Symptomatic patients should be monitored in the 
intensive care unit (ICU) for at least 72 hours. They should 
be receiving 100-percent oxygen and treated for fluid and 
electrolyte abnormalities. Serum calcium and magnesium 
and liver/kidney function tests are mandatory (68).
GI decontamination
Gastrointestinal decontamination is efficient within the 
first hour after rice tablet ingestion. As stomach acid 
increases the conversion of AlP to PH3, treatment with 3-5 % 
sodium bicarbonate can help, although its efficacy has not 
been proved (26, 69). Gastric lavage using a 1:10,000 
solution of potassium permanganate oxidizes PH3 to a non-
toxic phosphate. If it is administered in the first hour after 
ingestion, it can substantially decrease the amount of toxic 
PH3 (69, 70).
Administration of activated charcoal (1 g kg-1 in children 
and 50-100 g in adults) lowers phosphide absorption and 
alleviates latent signs/symptoms of poisoning. Although it 
is useful in a patient who has recently ingested a huge 
amount of AlP, its efficacy is limited and is therefore not 
recommended for routine treatment (69).
Some recommend the use of coconut oil to accompany 
routine treatment (63, 70), as it contains saturated fatty acids 
and seems to reduce the release of PH3 in gastric acid. 
Furthermore, coconut oil seems to coat the stomach mucosa 
and prevent PH3 absorption. This effect was reported after 
co-administration of 50 mL of coconut oil and 50 mL of 
sodium bicarbonate (70), but there is little other research 
evidence to make it part of routine treatment. Vegetable oils 
and liquid paraffin have also been reported to prevent PH3 
release from AlP in vitro, but there is only one case report 
to confirm it (70). Another promising treatment, according 
to Saidi and Shojaie (71), could be sweet almond oil, as it 
lowered AlP-induced death in rats, but its action has not 
been reported in human-beings. Hassanian-Moghaddam 
and Shahbazi (72) proposed the use of gastric ventilation 
to evacuate PH3 within minutes of rice tablet ingestion. 
More studies are needed to prove the efficacy of this method.
Cardiovascular support
Due to the cardiovascular effects of the toxin, ECG and 
cardiac monitoring are recommended in all patients. 
Primary resuscitation by administration of fluids and 
inotropes and checking central vein pressure (CVP) and 
pulmonary artery wedge pressure (PAWP) are also 
recommended (26, 73- 75). Norepinephrine, phenylephrine, 
dopamine, or dobutamine can be used to treat hypotension 
and persistent shock. However, vasopressors with greater 
activity at beta receptors (such as dopamine and dobutamine) 
can cause dysrhythmias and should be used with caution 
(26).
Cardiac arrhythmias are generally treated by anti-
arrhythmic medications, direct-current defibrillation, or 
temporary pacemaker. Digoxin is used to stabilise the left 
ventricle. Earlier case reports showed that primary 
administration of 0.5 mg of digoxin followed by 0.5 mg 
every six hours for the first day and 0.25 mg daily afterwards 
improved the patient's cardiovascular symptoms (73, 74). 
However, only a few studies have evaluated the efficacy of 
digoxin in the treatment of AlP poisoning, and it may be 
initiated in patients whose cardiac insufficiency has been 
confirmed by echocardiogram. 
S o m e  p h y s i c i a n s  r e c o m m e n d  i n d u c i n g 
hyperinsulinaemia-euglycaemia (HIE) as well as 
hyperventilation, as both trigger energy production from 
carbohydrates, reverse calcium, and improve myocyte 
contractions (62). Some report the use of intra-aortic balloon 
pump (IABP) for mechanical support of the heart in patients 
with toxic myocarditis, persistent shock or persistent cardiac 
complications of the poisoning (72, 75). Some persistent 
cases may require the implantation of a pacemaker (12). 
Extracorporeal membrane oxygenation is another recently 
suggested treatment with promising results (75, 76).
Respiratory support
One of the complications of AlP poisoning is the 
development of ARDS, which is treated as usual (26, 31). 
I f  the  pa t i en t  deve lops  pe r s i s t en t  cyanos i s , 
methaemoglobinaemia should be suspected and 1-2 mg kg-1 
of methylene blue should be intravenously administered 
over five minutes (21).
Other treatments
Sodium bicarbonate is used for the treatment of acidosis. 
If the patient has volume overload, haemodialysis (HD) can 
be performed, although it cannot expel PH3 from the blood 
(28). Infusing the patient with 1-4 L of 5-10 % dextrose in 
water (DW) is recommended to maintain serum glucose in 
the normal range. Hypoglycaemia, hypokalaemia, and 
metabolic acidosis are treated as usual (26, 31).
Ten millilitres of 10 % calcium gluconate is generally 
recommended to stabilise cell membranes. Administration 
of calcium gluconate or chloride is also recommended in 
case of hypocalcaemia-induced tetany (67, 77). Magnesium 
sulphate (MgSO4) is another cell membrane stabiliser with 
anti-oxidant properties to mitigate the effects of free radicals 
released by phosphine. In general, it has been shown that 
this treatment can decrease AlP-related mortality by 25 % 
(62). Different doses have been proposed for MgSO4 
administration including: a) 3 g in 3 h followed by 6 g in 
24 h for 3-5 days (3); b) 1 g as initial dose, followed by 1 g 
every hour for 2 h and 1-1.5 g every six hours for 5-7 days 
(7); and c) 1 g as initial dose, followed by 1 g for 3 h and 
then 1 g every six hours for five to seven days (78).
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However, due to the risk of hypermagnesemia (62), it 
seems that routine use of MgSO4 is not practical (26, 31). 
We therefore recommend magnesium administration with 
any of the above-mentioned protocols in patients with low 
or even normal serum magnesium levels. Daily serum 
magnesium monitoring can prevent hypermagnesemia 
during treatment.
Considering that N-acetylcysteine (NAC) can reverse 
cellular glutathione and magnesium storages and acts as an 
antioxidant, its effects in the supportive treatment of AlP 
have been investigated in rats and humans. In rats, NAC 
prolonged survival time, stabilised blood pressure and pulse 
rate, and prevented oxidative stress of the myocardium (79). 
In humans, NAC lowered mortality, hospitalisation time, 
and the frequency of intubation and mechanical ventilation 
(80). It increased blood pressure and kept it stable within 
the first 24 hours. Two methods have been proposed for 
NAC administration:
a) intravenous (IV) infusion of 150 mg kg-1 in 200 mL 
of 5 % DW over one hour, followed by 50 mg kg-1 in 500 mL 
of 5 % DW over four hours, and then 100 mg kg-1 in 
1000 mL of 5 % DW over 16 hours (37); or
b) IV infusion of 140 mg kg-1 followed by 70 mg kg-1 
every four hours for 17 doses.
However, the recommended IV injection dose for 
routine treatment is 50-100 mg kg-1 three times a day (67).
Administration of vitamin E seems to prevent hepatic 
destruction due to lipid peroxidation by phosphine (81). 
This effect, however, still needs to be confirmed by future 
studies. Administration of vitamin C (1 g every six hours) 
with 1 % methylene blue was successful against 
methaemoglobinaemia and haemolysis caused by PH3 (34). 
However, this treatment is generally not recommended 
because it may worsen patient's acidosis.
Other treatments such as melatonin, glutathione, and 
beta carotene have also been proposed and need further 
evaluation (72).
There is no report or evidence of steroid treatment 
efficacy in AlP poisoning, but we know that steroids act 
against inflammation, especially in the respiratory system 
(64).
Using hyperbaric oxygen prolonged survival time in 
rats but did not reduce mortality (82). This method has not 
been evaluated in humans.
Hydroxyethyl starch can stay in the vessels and prevent 
fluid and albumin shift to the tissues (83). However, there 
is no clinical information to support this effect in AlP 
poisoning.
Blood exchange is a questionable treatment in AlP 
poisoning (84, 85). Haemodialysis does not efficiently 
eliminate PH3 from blood, but can be used in patients with 
acute kidney failure, severe metabolic acidosis, or fluid 
overload (26). Administration of vasopressors, fresh blood, 
and bronchodilators are recommended when indicated.
If pulmonary oedema develops, and the patient is not 
hypotensive, diuretics can also be used.
Seizure should be treated with routine therapies, 
including benzodiazepines (67).
Both clinical and laboratory reports say that phosphine 
and aluminium inhibit acetylcholinesterase (AChE) and 
that pralidoxime may prove effective in restoring AChE 
activity. In rats, atropine and pralidoxime increased survival 
when administered five minutes after exposure to AlP. More 
studies are needed to prove the efficacy of oximes in the 
treatment of this poisoning (33). For the moment, these 
medications are not recommended for routine treatment.
Considering all of the above, the only recommended 
treatment of AlP poisoning is the general supportive one.
Prognosis and long-term complications
In ingestions of 500 mg or more the mortality rate is 30 
to 100 %. Most of the deaths are due to cardiovascular 
collapse within the first 12-24 hours (47, 62). After the first 
24 hours, deaths are mainly due to persistent shock, severe 
acidosis, and ARDS (85). Fulminant hepatic failure occurs 
within 72 hours and is another cause of death in these 
patients (3). Patients who have taken lower doses, expired 
tablets, or tablets exposed to air have a greater chance of 
survival. Vomiting and early supportive care can also 
increase the survival rate (12, 26).
Poorer prognosis is associated with higher phosphine 
levels, no vomiting after ingestion, hyperglycaemia, 
hyperkalaemia, hyponatraemia, hypernatraemia, 
hyperuricaemia, acidosis, leukocytosis, haemoconcentration, 
low prothrombin time, shock, methaemoglobinaemia, 
abnormal ECG, need for inotropes, need for mechanical 
ventilation, high Simplified Acute Physiology Score (SAPS) 
and Acute Physiology and Chronic Health Evaluation II 
(APACHE II), and low Glasgow coma scale (4, 8, 25, 26, 
60, 86- 89). The higher the phosphine blood level, the higher 
is the risk of death.
If no signs/symptoms are evident six hours after 
ingestion or inhalation, the patient will remain symptom-
free (76). With cardio-respiratory complications the 
prognosis is poor (67). Most of the deaths happen in the 
first 24 hours, and much depends on the severity of 
poisoning and the time between poisoning and treatment.
Some patients reported local GI complications in the 
first month after poisoning including dysphagia, oesophageal 
stricture, and oesophagotracheal fistula (90). It is 
recommended that all patients undergo GI evaluation using 
barium swallow and endoscopy before they are released 
from the hospital in order to detect these complications and 
treat them as soon as possible (3).
Cytogenetic and genetic evaluations have shown that 
PH3 is not mutagenic (90).
Prevention
Access to AlP tablets should be limited and controlled, 
in particular their over and below-the-counter sale. Most 
of the victims are people with suicidal intent, and we believe 
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that disseminating knowledge about this poison among lay 
people is not only useless but may also increase poisoning 
rate among people with suicidal intent. More effort should 
be made to disseminate and update knowledge among 
physicians, so that they can improve treatment and save 
more lives.
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Pregled otrovanja aluminijevim fosfidom i prijedlog dijagrama tijeka njegova liječenja
Primjena pesticida poput aluminijeva fosfida (AlP) raste iz godine u godinu, povoljno utječući na količinu i kakvoću 
poljoprivrednih proizvoda u mnogim zemljama u razvoju. Nažalost, AlP može uzrokovati i snažne kronične i akutne 
zdravstvene posljedice, koje su u zemljama poput Indije, Irana, Bangladeša i Jordana dosegnule zabrinjavajuće razmjere. 
U svijetu svake godine od otrovanja pesticidima umre gotovo 300.000 ljudi. Mnoge od tih smrti uzrokovane su aluminijevim 
fosfidom. Svrha je ovoga članka dati kratak pregled literature vezane uz otrovanje AlP-om te predložiti algoritam njegova 
liječenja koji se temelji na dosadašnjim spoznajama. U tu smo svrhu pregledali sve članke o liječenju otrovanja AlP-om 
od 2000. naovamo. Oslanjajući se na prilagođeni Delphi-dizajn, osmislili smo koristan dijagram tijeka koji bi se mogao 
koristiti kao vodič kroz liječenje otrovanja aluminijevim fosfidom u hitnim službama.
KLJUČNE RIJEČI: hitna služba; liječenje otrovanja; pesticidi; pregled literature
